Anzeige
Mehr »
Mittwoch, 20.05.2026 - Börsentäglich über 12.000 News
Bewertet mit 8$ - Preis:139$: Peer-Übernahmen brachten Anlegern dreistellige Gewinne
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41556 | ISIN: US87978U2078 | Ticker-Symbol: 3OS0
NASDAQ
19.05.26 | 21:58
1,800 US-Dollar
+1,12 % +0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TEMPEST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TEMPEST THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TEMPEST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTempest Therapeutics, Inc. - 10-Q, Quarterly Report1
DoTempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update181Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and...
► Artikel lesen
TEMPEST THERAPEUTICS Aktie jetzt für 0€ handeln
06.05.Tempest Therapeutics: Tempest Presents Clinical Update at ISCT 2026 Annual Meeting3
06.05.Tempest Therapeutics, Inc. - 8-K, Current Report2
29.04.Tempest Therapeutics: Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting9
30.03.Tempest Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
30.03.Tempest Therapeutics GAAP EPS of -$6.33 misses by $0.234
30.03.Tempest Therapeutics: Tempest Reports Year End 2025 Financial Results and Provides Business Update302Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing...
► Artikel lesen
30.03.Tempest Therapeutics, Inc. - 10-K, Annual Report3
30.03.Tempest Therapeutics, Inc. - 8-K, Current Report-
23.03.Tempest Therapeutics raises $2 million in private placement8
23.03.Tempest Therapeutics, Inc. - 8-K, Current Report1
11.03.Tempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026406Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned...
► Artikel lesen
25.02.Tempest Therapeutics reports complete response in myeloma trial8
25.02.Tempest Therapeutics, Inc. - 8-K, Current Report2
25.02.Tempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026497100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade - 3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression...
► Artikel lesen
06.02.Tempest Therapeutics, Inc. - 8-K, Current Report7
04.02.Tempest Therapeutics stärkt Pipeline durch Übernahme von CAR-T-Therapien6
04.02.Tempest Therapeutics completes acquisition of CAR-T assets2
04.02.Tempest Therapeutics: Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets769All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in...
► Artikel lesen
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1